문의 support@wisest.co.kr
글로벌 뉴스
글로벌 주요 증시에 상장된 종목 뉴스를 실시간 수집하고 핵심 내용을 인공지능으로 요약 및 번역합니다.
제목을 터치하면 요약된 뉴스 기사와 함께 AI분석(주가 영향 분석)을 볼 수 있습니다.
번역중... Clearwater Sets Sails For 55th Year: Hudson Valley Week In Review
2024-04-12T20:37:23.000Z | patch.com
Community Corner Clearwater Sets Sails For 55th Year: Hudson Valley Week In Review Plus eclipse offers learning moments, Regeneron accused of inflating Medicare reimbursements and former city manager serves as interim.
The Hudson Valley Week in Review is a roundup of some of the most-read stories from the region's hyperlocal sites.
(Patch graphic)HUDSON VALLEY, NY — There was a lot of news over the past week in the Hudson Valley.
In case you missed some of it, here are a few of the most-read stories from the region’s hyperlocal sites.
HV No Stranger To Toxic Water Chemicals EPA Will Limit StrictlyThe largest water supplier in the Hudson Valley supports the Environmental Protection Agency's new rules about PFAS.
AI로 요약한 내용입니다. 본문을 터치하면 번역문이 표시됩니다.
번역중... Community Corner Clearwater Sets Sails For 55th Year: Hudson Valley Week In Review Plus eclipse offers learning moments, Regeneron accused of inflating Medicare reimbursements and former city manager serves as interim.
The Hudson Valley Week in Review is a roundup of some of the most-read stories from the region's hyperlocal sites.
(Patch graphic)HUDSON VALLEY, NY — There was a lot of news over the past week in the Hudson Valley.
In case you missed some of it, here are a few of the most-read stories from the region’s hyperlocal sites.
HV No Stranger To Toxic Water Chemicals EPA Will Limit StrictlyThe largest water supplier in the Hudson Valley supports the Environmental Protection Agency's new rules about PFAS.
AI로 번역한 내용입니다. 본문을 터치하면 영어 원문이 표시됩니다.
번역중... Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea
2024-04-12T19:03:16.000Z | zacks.com
This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system.
Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month.
A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.
Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.
Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
AI로 요약한 내용입니다. 본문을 터치하면 번역문이 표시됩니다.
번역중... This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system.
Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month.
A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.
Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.
Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
AI로 번역한 내용입니다. 본문을 터치하면 영어 원문이 표시됩니다.
번역중... Food Allergy Pipeline Landscape Research Report 2024: Comprehensive Insights About 30+ Companies and 35+ Pipeline Drugs
2024-04-12T14:35:08.000Z | finance.yahoo.com
Dublin, April 12, 2024 (GLOBE NEWSWIRE) -- The "Food Allergy - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Food Allergies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights
AI로 요약한 내용입니다. 본문을 터치하면 번역문이 표시됩니다.
번역중... Dublin, April 12, 2024 (GLOBE NEWSWIRE) -- The "Food Allergy - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Food Allergies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights
AI로 번역한 내용입니다. 본문을 터치하면 영어 원문이 표시됩니다.
번역중... Jefferies raises Regeneron shares target on limited impact view
2024-04-12T13:26:27.000Z | investing.com
On Friday, Jefferies maintained a Buy rating on Regeneron (NASDAQ: ) Pharmaceuticals (NASDAQ: REGN) and increased the shares price target to $1,060 from $1,025.
Despite the legal challenge, Jefferies anticipates a minimal financial impact on Regeneron.
Further supporting the limited financial threat to Regeneron, Jefferies suggests that the final settlement charges could be significantly lower, possibly under $50 million.
InvestingPro InsightsIn light of the recent developments surrounding Regeneron Pharmaceuticals, it's important to consider the company's financial health and market performance.
Investors may find these metrics particularly relevant as they assess the potential impact of the DoJ's legal action on Regeneron's stock.
AI로 요약한 내용입니다. 본문을 터치하면 번역문이 표시됩니다.
번역중... On Friday, Jefferies maintained a Buy rating on Regeneron (NASDAQ: ) Pharmaceuticals (NASDAQ: REGN) and increased the shares price target to $1,060 from $1,025.
Despite the legal challenge, Jefferies anticipates a minimal financial impact on Regeneron.
Further supporting the limited financial threat to Regeneron, Jefferies suggests that the final settlement charges could be significantly lower, possibly under $50 million.
InvestingPro InsightsIn light of the recent developments surrounding Regeneron Pharmaceuticals, it's important to consider the company's financial health and market performance.
Investors may find these metrics particularly relevant as they assess the potential impact of the DoJ's legal action on Regeneron's stock.
AI로 번역한 내용입니다. 본문을 터치하면 영어 원문이 표시됩니다.
번역중... Regeneron Accused Of Inflating Medicare Reimbursement | PM
2024-04-11T20:22:18.000Z | patch.com
Community Corner Regeneron Accused Of Inflating Medicare Reimbursement | Patch PM Interim Village Manager Named; Road Rage Yields Felony Charges: All That JazzPatch PM is a compilation of news of the day from around the Hudson Valley.
(Patch graphic)HUDSON VALLEY, NY — Share-worthy stories from the Hudson Valley Patch network to talk about tonight:Sleepy Hollow Jazz Festival Concert To Feature Regional SchoolsBefore the concert, there will be workshops and clinics for the student musicians.
The Patch community platform includes communities in the mid- and lower Hudson Valley, Long Island, New York City, New Jersey, and Connecticut.
Thank you for reading.
AI로 요약한 내용입니다. 본문을 터치하면 번역문이 표시됩니다.
번역중... Community Corner Regeneron Accused Of Inflating Medicare Reimbursement | Patch PM Interim Village Manager Named; Road Rage Yields Felony Charges: All That JazzPatch PM is a compilation of news of the day from around the Hudson Valley.
(Patch graphic)HUDSON VALLEY, NY — Share-worthy stories from the Hudson Valley Patch network to talk about tonight:Sleepy Hollow Jazz Festival Concert To Feature Regional SchoolsBefore the concert, there will be workshops and clinics for the student musicians.
The Patch community platform includes communities in the mid- and lower Hudson Valley, Long Island, New York City, New Jersey, and Connecticut.
Thank you for reading.
AI로 번역한 내용입니다. 본문을 터치하면 영어 원문이 표시됩니다.
번역중... Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug
2024-04-11T18:12:20.000Z | benzinga.com
The U.S. Justice Department has leveled allegations against Regeneron Pharmaceuticals REGN, accusing the company of manipulating Medicare’s drug-pricing system for its macular degeneration drug, Eylea (aflibercept).
In a federal court complaint filed in Boston, the department claims that Regeneron inflated the average sales price of Eylea, a move that significantly impacted Medicare expenses.
According to the lawsuit, Reuters highlighted that Regeneron purportedly failed to disclose substantial payments to drug distributors to subsidize Eylea’s purchases.
The lawsuit alleges that Regeneron’s failure to report all price concessions for Eylea violates the False Claims Act, resulting in inflated Medicare costs.
Acting U.S. Attorney Joshua Levy of Massachusetts emphasized that Regeneron’s actions greatly inflated Medicare costs and boosted its revenues.
AI로 요약한 내용입니다. 본문을 터치하면 번역문이 표시됩니다.
번역중... The U.S. Justice Department has leveled allegations against Regeneron Pharmaceuticals REGN, accusing the company of manipulating Medicare’s drug-pricing system for its macular degeneration drug, Eylea (aflibercept).
In a federal court complaint filed in Boston, the department claims that Regeneron inflated the average sales price of Eylea, a move that significantly impacted Medicare expenses.
According to the lawsuit, Reuters highlighted that Regeneron purportedly failed to disclose substantial payments to drug distributors to subsidize Eylea’s purchases.
The lawsuit alleges that Regeneron’s failure to report all price concessions for Eylea violates the False Claims Act, resulting in inflated Medicare costs.
Acting U.S. Attorney Joshua Levy of Massachusetts emphasized that Regeneron’s actions greatly inflated Medicare costs and boosted its revenues.
AI로 번역한 내용입니다. 본문을 터치하면 영어 원문이 표시됩니다.
번역중... Regeneron Fraudulently Inflated Medicare Reimbursement On Drug: Feds
2024-04-11T18:11:43.000Z | patch.com
Crime & Safety Regeneron Fraudulently Inflated Medicare Reimbursement On Drug: Feds The company said that the allegations are without merit and it "will vigorously defend itself in court."
The U.S. Department of Justice accused Regeneron Pharmaceuticals Inc. of fraudulently inflating Medicare reimbursement for a drug that treats age-related macular degeneration.
(Google Maps)TARRYTOWN, NY — The federal government has accused Regeneron Pharmaceuticals Inc., which is based in Tarrytown, of fraudulently inflating Medicare reimbursement for one of its drugs.
The U.S. Department of Justice said Regeneron inflated Medicare reimbursement rates for Eylea, an anti-vascular drug approved by the Food and Drug Administration to treat, among other conditions, age-related macular degeneration, a usually age-related condition that impairs vision.
“The Government’s complaint demonstrates a fundamental misunderstanding of drug price reporting standards,” Kwok said.
AI로 요약한 내용입니다. 본문을 터치하면 번역문이 표시됩니다.
번역중... Crime & Safety Regeneron Fraudulently Inflated Medicare Reimbursement On Drug: Feds The company said that the allegations are without merit and it "will vigorously defend itself in court."
The U.S. Department of Justice accused Regeneron Pharmaceuticals Inc. of fraudulently inflating Medicare reimbursement for a drug that treats age-related macular degeneration.
(Google Maps)TARRYTOWN, NY — The federal government has accused Regeneron Pharmaceuticals Inc., which is based in Tarrytown, of fraudulently inflating Medicare reimbursement for one of its drugs.
The U.S. Department of Justice said Regeneron inflated Medicare reimbursement rates for Eylea, an anti-vascular drug approved by the Food and Drug Administration to treat, among other conditions, age-related macular degeneration, a usually age-related condition that impairs vision.
“The Government’s complaint demonstrates a fundamental misunderstanding of drug price reporting standards,” Kwok said.
AI로 번역한 내용입니다. 본문을 터치하면 영어 원문이 표시됩니다.
번역중... INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
2024-04-11T17:19:24.000Z | benzinga.com
Loading... Loading...LOS ANGELES, April 11, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") REGN for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:The Schall Law FirmBrian Schall, Esq.
AI로 요약한 내용입니다. 본문을 터치하면 번역문이 표시됩니다.
번역중... Loading... Loading...LOS ANGELES, April 11, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") REGN for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:The Schall Law FirmBrian Schall, Esq.
AI로 번역한 내용입니다. 본문을 터치하면 영어 원문이 표시됩니다.
번역중... RBC maintains stock price target on Regeneron amid DOJ complaint
2024-04-11T16:23:56.000Z | investing.com
On Thursday, RBC Capital maintained its Sector Perform rating and $1,189.00 stock price target for Regeneron (NASDAQ: ) Pharmaceuticals shares, traded on NASDAQ:REGN, despite a recent legal development.
The Department of Justice (DOJ) has filed a complaint against Regeneron, alleging the company fraudulently inflated Medicare reimbursement rates for its drug Eylea.
The complaint focuses on Regeneron's practice of reimbursing credit card transaction fees to distributors when physicians purchased Eylea using credit cards.
RBC Capital had discussions with Regeneron regarding the allegations.
RBC Capital pointed out that Regeneron's stock price has been declining, making it increasingly attractive for investment (20.5x forward EPS, or 14.5x after Sanofi (NASDAQ: ) development payments are complete).
AI로 요약한 내용입니다. 본문을 터치하면 번역문이 표시됩니다.
번역중... On Thursday, RBC Capital maintained its Sector Perform rating and $1,189.00 stock price target for Regeneron (NASDAQ: ) Pharmaceuticals shares, traded on NASDAQ:REGN, despite a recent legal development.
The Department of Justice (DOJ) has filed a complaint against Regeneron, alleging the company fraudulently inflated Medicare reimbursement rates for its drug Eylea.
The complaint focuses on Regeneron's practice of reimbursing credit card transaction fees to distributors when physicians purchased Eylea using credit cards.
RBC Capital had discussions with Regeneron regarding the allegations.
RBC Capital pointed out that Regeneron's stock price has been declining, making it increasingly attractive for investment (20.5x forward EPS, or 14.5x after Sanofi (NASDAQ: ) development payments are complete).
AI로 번역한 내용입니다. 본문을 터치하면 영어 원문이 표시됩니다.
번역중... Gas prices are hurting biotech
2024-04-11T13:40:32.000Z | statnews.com
Want to stay on top of the science and politics driving biotech today?
Damian here with a look at a biotech deal with a lengthy backstory, the tyranny of gas prices, and the latest shakeup at BIO.
Gas prices are hurting biotechThe biggest index of biotech stocks turned red for the year, and it had nothing to do with clinical trials, drug revenues, or pharmaceutical mergers.
Among the major culprits is gas: It’s expensive, and combined with housing it contributed more than half of the monthly increase in the CPI.
The XBI, a closely watched index of biotech stocks, fell about 2% on the news.
AI로 요약한 내용입니다. 본문을 터치하면 번역문이 표시됩니다.
번역중... Want to stay on top of the science and politics driving biotech today?
Damian here with a look at a biotech deal with a lengthy backstory, the tyranny of gas prices, and the latest shakeup at BIO.
Gas prices are hurting biotechThe biggest index of biotech stocks turned red for the year, and it had nothing to do with clinical trials, drug revenues, or pharmaceutical mergers.
Among the major culprits is gas: It’s expensive, and combined with housing it contributed more than half of the monthly increase in the CPI.
The XBI, a closely watched index of biotech stocks, fell about 2% on the news.
AI로 번역한 내용입니다. 본문을 터치하면 영어 원문이 표시됩니다.